Unusual Cutaneous Reaction with Erlotinib: A Brief Report with Current Review of Management of Tyrosine Kinase Inhibitor-associated Cutaneous Toxicity
Tyrosine kinase inhibitors (TKIs) have emerged as the preferred choice of treatment for various tumors as a result of better outcomes and quality of life without the debilitating side effects of cytotoxic chemotherapy. Erlotinib is a TKI against epidermal growth factor receptor that is commonly used...
Saved in:
Main Authors: | Aashita, Vikas Yadav, Pragyat Thakur, Anuja Kapoor |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
Series: | Journal of Radiation and Cancer Research |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/jrcr.jrcr_12_24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association between efficacy and skin rash following treatment with the lapatinib in metastatic breast cancer
by: Suleyman Temiz, et al.
Published: (2016-04-01) -
Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem
by: A. S. Polonskaia, et al.
Published: (2022-02-01) -
Botriomicosis asociada a tratamiento con erlotinib en una paciente con adenocarcinoma de pulmón
by: Claudia Montoya, et al.
Published: (2019-08-01) -
Acneiform rash — skin toxic reaction to the use of EGFR inhibitors
by: E. A. Shatokhina, et al.
Published: (2019-01-01) -
Bullous fixed drug eruption due to erlotinib: A rare case report
by: Kallolinee Samal, et al.
Published: (2025-07-01)